본문으로 건너뛰기
← 뒤로

Current status of treatment for esophagojejunostomy leakage after total gastrectomy in patients with gastric cancer: a multicenter retrospective study in Korea.

코호트 1/5 보강
Journal of minimally invasive surgery 2025 Vol.28(4) p. 184-192
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
577 patients who underwent total gastrectomy or proximal gastrectomy with double tract reconstruction at nine institutions from 2003 to 2024, 196 (3.
I · Intervention 중재 / 시술
total gastrectomy or proximal gastrectomy with double tract reconstruction at nine institutions from 2003 to 2024, 196 (3
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Over the past two decades, management of EJL has shifted toward endoscopic approaches. Endoscopic therapies yield superior clinical outcomes and should be considered a primary option for appropriate candidates.

Kim MC, Jung MR, Noh JJ, Kang S, Chung JH, Park JH, Kim TH, Park JK, Kim Y, Seo SH, Kim SE, Kwon OK, Park JY, Park KB, Hwang SH, Lee SH, Lee YJ, Jeong SH, Jeon TY, Kim DH, Choi CI, Yoon KY, Seo KW, Kim KH, Oh SH, Kim KH

📝 환자 설명용 한 줄

[PURPOSE] Esophagojejunostomy leakage (EJL) remains one of the most critical complications following total gastrectomy for gastric cancer.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Kim MC, Jung MR, et al. (2025). Current status of treatment for esophagojejunostomy leakage after total gastrectomy in patients with gastric cancer: a multicenter retrospective study in Korea.. Journal of minimally invasive surgery, 28(4), 184-192. https://doi.org/10.7602/jmis.2025.28.4.184
MLA Kim MC, et al.. "Current status of treatment for esophagojejunostomy leakage after total gastrectomy in patients with gastric cancer: a multicenter retrospective study in Korea.." Journal of minimally invasive surgery, vol. 28, no. 4, 2025, pp. 184-192.
PMID 41399049

Abstract

[PURPOSE] Esophagojejunostomy leakage (EJL) remains one of the most critical complications following total gastrectomy for gastric cancer. This study aimed to evaluate the evolving therapeutic approaches and clinical outcomes of EJL using data from a large-scale multicenter retrospective cohort.

[METHODS] Among 6,577 patients who underwent total gastrectomy or proximal gastrectomy with double tract reconstruction at nine institutions from 2003 to 2024, 196 (3.0%) developed EJL. Of these, 162 patients with comprehensive clinical data were included in the final analysis. The study examined treatment modalities, changes in management over time, patient characteristics, surgical variables, and clinical outcomes. Four groups were defined according to treatment approach: conservative, endoscopic, reoperation, and multimodal (combined) therapy.

[RESULTS] Endoscopic therapy was first introduced in 2011 and has progressively supplanted reoperation, now comprising 32.5% of cases. The average time to EJL diagnosis was 8.4 days after surgery. Overall in-hospital mortality was 6.1% (10/162). When conservative management was excluded, endoscopic treatment demonstrated the highest rate of therapeutic success (94.3%, = 0.004). Both the duration until diet resumption and length of hospital stay were notably reduced in the endoscopic and conservative groups compared with reoperation and multimodal therapy ( < 0.001). Moreover, although the highest post-leakage hospitalization costs were observed with multimodal treatment ( < 0.001), overall hospitalization expenses were significantly lower for patients managed conservatively or with endoscopic intervention ( < 0.001).

[CONCLUSION] Over the past two decades, management of EJL has shifted toward endoscopic approaches. Endoscopic therapies yield superior clinical outcomes and should be considered a primary option for appropriate candidates.

🏷️ 키워드 / MeSH

같은 제1저자의 인용 많은 논문 (3)

🟢 PMC 전문 열기